Company news

Catalyst Pharmaceuticals, Inc. news in 2023

Catalyst Pharmaceuticals, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Catalyst Pharmaceuticals Announces FIRDAPSE® New Drug Application Submitted in Japan by Partner DyDo Pharma

December 17, 2023

Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2024 List of America's Most Successful Small-Cap Companies

December 4, 2023

Catalyst Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer and Other Executive Promotions

December 3, 2023

Catalyst Pharmaceuticals To Participate in Piper Sandler 35th Annual Healthcare Conference

November 15, 2023

Catalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results and Corporate Update

November 7, 2023

Catalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE®

November 1, 2023

Catalyst Pharmaceuticals Partners with Sofie's Journey to Bring Focus on Epilepsy at the 11th Annual Epilepsy Awareness and Education Expo

October 29, 2023

Catalyst Pharmaceuticals Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals

October 25, 2023

Catalyst Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 8, 2023

October 22, 2023

Catalyst Pharmaceuticals Appoints Richard J. Daly as Chief Executive Officer

October 18, 2023

Catalyst Pharmaceuticals Announces FDA Acceptance of the Supplemental New Drug Application for FIRDAPSE®

October 12, 2023

Catalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare Conference

September 17, 2023

Catalyst Pharmaceuticals Announces Abstract on Lambert Eaton Myasthenic Syndrome (LEMS) to be Presented at the Upcoming IASLC 2023 World Conference of Lung Cancer

August 15, 2023

Catalyst Pharmaceuticals Announces Multiple Abstracts on FYCOMPA® (Perampanel) from Eisai Co, Ltd., to be Presented at the 35th International Epilepsy Congress

August 13, 2023

Catalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results and Provides Corporate Update

August 8, 2023

Patrick J. McEnany Announces Intention to Retire as CEO of Catalyst Pharmaceuticals by Year-End

July 24, 2023

Catalyst Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 9, 2023

July 23, 2023

Catalyst Pharmaceuticals Acquires Exclusive North American License For Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals

July 18, 2023

Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals

June 19, 2023

Catalyst Pharmaceuticals Reports Positive Momentum in Second Quarter 2023

May 31, 2023

Catalyst Pharmaceuticals Appoints Tamar Thompson to its Board of Directors

May 29, 2023

Catalyst Pharmaceuticals Reports Record First Quarter 2023 Results, Achieving 98% Total Revenue Growth Year-over-Year

May 9, 2023

Catalyst Pharmaceuticals Advances sNDA Submission Plans To Increase Indicated Maximum Dose For FIRDAPSE® From 80 mg Per Day To 100 mg Per Day

May 8, 2023

Catalyst Pharmaceuticals Announces Release of Inaugural ESG Report

April 30, 2023

Catalyst Pharmaceuticals to Report First Quarter 2023 Financial Results on May 10, 2023

April 23, 2023

Catalyst Pharmaceuticals Announces Third-Party Abstracts on FYCOMPA® (Perampanel) to be Presented at the Upcoming American Academy of Neurology 2023 Annual Meeting

April 19, 2023

Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

March 14, 2023

Catalyst Pharmaceuticals Announces a Recent Third-Party Publication in Peer-Reviewed Journal Epilepsia Showing Perampanel (FYCOMPA®) Demonstrated High Efficacy in Patients with Rare Genetic Epilepsies

March 7, 2023

Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on March 15, 2023

February 28, 2023

Catalyst Pharmaceuticals to Ring the Nasdaq Closing Bell in Honor of International Rare Disease Day

February 21, 2023

Catalyst Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2022 Total Revenues and Provides Full Year 2023 Revenue Guidance

February 6, 2023

Catalyst Pharmaceuticals Completes the Acquisition of U.S. Rights to FYCOMPA® (Perampanel) CIII

January 24, 2023

Catalyst Pharmaceuticals Notified of Abbreviated New Drug Application Filing for FIRDAPSE®

January 22, 2023

Catalyst Pharmaceuticals Comments on FDA's Announcement of its Position on Orphan Drug Exclusivity In Light of the 11th Circuit Decision in Catalyst Pharmaceuticals, Inc. v. Becerra

January 22, 2023

Calls in 2023

Decks in 2023